Animal Models to Study the Mutational Landscape for Oral Cavity and Oropharyngeal Cancers

por Spiotto, Michael T., Pytynia, Matthew, Liu, Gene-Fu F., Ranck, Mark C., Widau, Ryan
Publicado 2013

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)

por Arkenau, Hendrik‐Tobias, Martin‐Liberal, Juan, Calvo, Emiliano, Penel, Nicolas, Krebs, Matthew G., Herbst, Roy S., Walgren, Richard A., Widau, Ryan C., Mi, Gu, Jin, Jin, Ferry, David, Chau, Ian
Publicado 2018

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab

por Reig, Maria, Galle, Peter R., Kudo, Masatoshi, Finn, Richard, Llovet, Josep M., Metti, Andrea L., Schelman, William R., Liang, Kun, Wang, Chunxiao, Widau, Ryan C., Abada, Paolo, Zhu, Andrew X.
Publicado 2020

Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2

por Finn, Richard S, Yau, Thomas, Hsu, Chih-Hung, De Toni, Enrico N, Goyal, Lipika, Galle, Peter R, Qin, ShuKui, Rao, Sujata, Sun, Fangfang, Wang, Chunxiao, Widau, Ryan C, Zhu, Andrew X
Publicado 2022

Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials

por Llovet, Josep M., Singal, Amit G., Villanueva, Augusto, Finn, Richard S., Kudo, Masatoshi, Galle, Peter R., Ikeda, Masafumi, Callies, Sophie, McGrath, Louise M., Wang, Chunxiao, Abada, Paolo, Widau, Ryan C., Gonzalez-Gugel, Elena, Zhu, Andrew X.
Publicado 2022

Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multic...

por Shao, Guoliang, Bai, Yuxian, Yuan, Xianglin, Chen, Xiaomin, Gu, Shanzhi, Gu, Kangsheng, Hu, Chunhong, Liang, Houjie, Guo, Yabing, Wang, Jufeng, Yen, Chia-Jui, Lee, Victor Ho-Fun, Wang, Chunxiao, Widau, Ryan C., Zhang, Wanli, Liu, Junjun, Zhang, Qiang, Qin, Shukui
Publicado 2022

Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab

por Zhu, Andrew X., Finn, Richard S., Kang, Yoon-Koo, Yen, Chia-Jui, Galle, Peter R., Llovet, Josep M., Assenat, Eric, Brandi, Giovanni, Motomura, Kenta, Ohno, Izumi, Daniele, Bruno, Vogel, Arndt, Yamashita, Tatsuya, Hsu, Chih-Hung, Gerken, Guido, Bilbruck, John, Hsu, Yanzhi, Liang, Kun, Widau, Ryan C., Wang, Chunxiao, Abada, Paolo, Kudo, Masatoshi
Publicado 2021

Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2

por Kudo, Masatoshi, Galle, Peter R., Brandi, Giovanni, Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S., Llovet, Josep M., Assenat, Eric, Merle, Philippe, Chan, Stephen L., Palmer, Daniel H., Ikeda, Masafumi, Yamashita, Tatsuya, Vogel, Arndt, Huang, Yi-Hsiang, Abada, Paolo B., Yoshikawa, Reigetsu, Shinozaki, Kenta, Wang, Chunxiao, Widau, Ryan C., Zhu, Andrew X.
Publicado 2020